Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.

This study has been completed.
Information provided by (Responsible Party):
Centocor, Inc. Identifier:
First received: December 22, 2005
Last updated: May 22, 2015
Last verified: May 2015